...
首页> 外文期刊>Hematology >Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
【24h】

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

机译:长期使用α-干扰素2b治疗真性红细胞增多症后,残留病最小,骨髓正常。持续完全血液学缓解的7例患者的分子反应模式的报告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Polycythemia vera (PV) is characterized by the presence of the JAK2V617F mutation in virtually all patients. Several studies have shown that the JAK2V617F mutational load decreases during treatment with alpha-interferon 2. We report on molecular and histomorphological bone marrow responses in seven PV patients with profound molecular responses during and after long-term treatment with alpha-interferon 2b. All patients obtained a major molecular response (MMR). Subsequently all patients discontinued alpha-interferon and sustained complete hematological remission with a follow-up period of median 10 months (range 4-30 months). Complete normalization of the bone marrow was seen in three of five patients. Long term treatment with IFN2b is able to induce 'minimal residual disease' with very low JAK2 V617F allele burden and may induce profound, and in some patients total, regression of histomorphological bone marrow features of PV. Finally, hematological remissions and major molecular responses can be sustained after discontinuation of long-term treatment with IFN2b.
机译:真性红细胞增多症(PV)的特征在于几乎所有患者中都存在JAK2V617F突变。几项研究表明,在用α-干扰素2治疗期间,JAK2V617F突变负荷降低。我们报道了7名PV患者在长期使用α-干扰素2b治疗期间和之后发生的分子和组织形态学骨髓反应,这些患者具有深远的分子反应。所有患者均获得重大分子反应(MMR)。随后,所有患者停用α-干扰素并持续完全血液学缓解,随访时间中位数为10个月(4-30个月)。五分之三的患者中看到骨髓完全正常化。 IFN2b的长期治疗能够在极低的JAK2 V617F等位基因负担下诱导“最小残留病”,并可能引起PV的组织形态学骨髓特征的深刻(甚至在某些患者中)全面退化。最后,中断长期用IFN2b治疗后,血液学缓解和主要分子反应仍可维持。

著录项

  • 来源
    《Hematology》 |2009年第6期|331-334|共4页
  • 作者单位

    Department of Hematology, Odense University Hospital, Denmark;

    Department of Pathology, Odense University Hospital, Denmark;

    Department of Pathology, Odense University Hospital, Denmark;

    Department of Pathology, Herlev Hospital, Denmark;

    Department of Internal Medicine, Section of Hematology, Karolinska Institute at Stockholm South Hospital, Stockholm, Sweden;

    Department of Hematology, Odense University Hospital, Denmark;

    Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

    Department of Clinical Genetics, Rigshospitalet, Denmark;

    Department of Hematology- Oncology, Roskilde Hospital, Roskilde, Denmark;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号